NewAmsterdam Pharma Company NV
NAMS21.458USD
+0.178+0.84%
Market hours （ET）Quotes delayed by 15 min
USD0.000Pre-market (ET)
2.41BMarket Cap
LossP/E TTM
NewAmsterdam Pharma Company NV
21.458
+0.178+0.84%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
33.21%-36.47M
---37.48M
73.39%-12.50M
-84.20%-53.98M
-71.36%-54.60M
---46.98M
---29.30M
---31.86M
Net income from continuing operations
57.85%-39.53M
---92.18M
64.68%-16.65M
-1.87%-39.01M
-123.16%-93.77M
---47.13M
---38.29M
---42.02M
Operating gains losses
246.67%52.00K
--51.00K
100.00%28.00K
46.15%19.00K
66.67%15.00K
--14.00K
--13.00K
--9.00K
Other non-cash items
-298.55%-4.80M
--7.64M
-248.15%-4.68M
1264.38%996.00K
178.92%2.42M
--3.16M
--73.00K
---3.06M
Change in working capital
202.11%10.35M
---7.98M
100.48%28.00K
-587.47%-14.59M
-1647.76%-10.14M
---5.88M
--2.99M
---580.00K
-Change in prepaid expenses
1576.88%16.03M
---8.69M
83.84%-493.00K
-269.36%-9.23M
167.66%956.00K
---3.05M
--5.45M
---1.41M
-Change in other current liabilities
-112.56%-2.98M
--1.51M
39.29%-1.79M
-32.73%-2.28M
56.81%-1.40M
---2.94M
---1.72M
---3.24M
Cash from non-recurring investing activities
Cash from operating activities
33.21%-36.47M
---37.48M
73.39%-12.50M
-84.20%-53.98M
-71.36%-54.60M
---46.98M
---29.30M
---31.86M
Investing cash flow
Net cash from continuing investing activities
-95.84%16.00K
--3.00K
733.33%75.00K
4080.00%209.00K
5400.00%385.00K
--9.00K
--5.00K
--7.00K
Capital expenditures
-95.84%16.00K
--3.00K
733.33%75.00K
4080.00%209.00K
5400.00%385.00K
--9.00K
--5.00K
--7.00K
Net cash flow from disposal of fixed assets
-95.84%16.00K
--3.00K
733.33%75.00K
4080.00%209.00K
5400.00%385.00K
--9.00K
--5.00K
--7.00K
Net cash flow from investment products
--2.87M
---62.18M
----
----
----
----
----
----
Cash from non-current investing activities
Net cash flow from investing activities
841.56%2.85M
---62.18M
-733.33%-75.00K
-4080.00%-209.00K
-5400.00%-385.00K
---9.00K
---5.00K
---7.00K
Financing cash flow
Cash flow from continuous financing activities
-96.71%6.52M
--456.61M
-68.82%58.00K
-26.46%4.66M
8185.12%198.18M
--186.00K
--6.33M
--2.39M
Net cash flow from common stock issuance/repurchase
----
--455.03M
--0.00
--0.00
--190.48M
----
--0.00
--0.00
Proceeds from stock option exercised by employees
1700.45%7.92M
--1.27M
-68.65%58.00K
-100.00%0.00
--440.00K
--185.00K
--105.00K
--0.00
Proceeds from issuance of warrants
-97.91%183.00K
--340.00K
-100.00%0.00
-25.22%4.66M
266.35%8.76M
--1.00K
--6.23M
--2.39M
Net cash flow from other financing activities
-5.45%-1.59M
---25.00K
--0.00
--0.00
---1.50M
----
--0.00
--0.00
Net cash from non-recurrent financing activities
Net cash from financing activities
-96.71%6.52M
--456.61M
-68.82%58.00K
-26.46%4.66M
8185.12%198.18M
--186.00K
--6.33M
--2.39M
Net cash flow
Beginning cash balance
126.68%771.74M
--422.73M
3.36%430.71M
9.03%481.15M
-27.21%340.45M
--416.71M
--441.31M
--467.73M
Current period cash flow changes
-116.58%-23.32M
--349.01M
83.51%-7.98M
-104.99%-50.44M
632.62%140.70M
---48.40M
---24.61M
---26.42M
Effect of exchange rate changes
251.08%3.77M
---7.94M
383.75%4.54M
44.23%-909.00K
-181.52%-2.50M
---1.60M
---1.63M
--3.06M
Ending cash balance
55.55%748.42M
--771.74M
14.78%422.73M
3.36%430.71M
9.03%481.15M
--368.31M
--416.71M
--441.31M
Free cash flow
33.65%-36.48M
---37.48M
73.23%-12.58M
-84.88%-54.19M
-72.54%-54.99M
---46.98M
---29.31M
---31.87M
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
